Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-25T19:20:03.945Z Has data issue: false hasContentIssue false
  • English
  • Français

Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD)

Published online by Cambridge University Press:  10 August 2012

Asuka Katsuki ,
Reiji Yoshimura ,
Taro Kishi ,
Hikaru Hori ,
Wakako Umene-Nakano ,
Atsuko Ikenouchi-Sugita ,
Kenji Hayashi ,
Kiyokazu Atake ,
Nakao Iwata  and
Jun Nakamura
Asuka Katsuki
Affiliation:
Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Japan
Reiji Yoshimura*
Affiliation:
Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Japan
Taro Kishi
Affiliation:
Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, New York, USA Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan
Hikaru Hori
Affiliation:
Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Japan
Wakako Umene-Nakano
Affiliation:
Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Japan
Atsuko Ikenouchi-Sugita
Affiliation:
Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Japan
Kenji Hayashi
Affiliation:
Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Japan
Kiyokazu Atake
Affiliation:
Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Japan
Nakao Iwata
Affiliation:
Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan
Jun Nakamura
Affiliation:
Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Japan
*
*Address for correspondence: Reiji Yoshimura, Department of Psychiatry, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kiyakyushu 8078555, Japan. (Email yoshi621@med.uoeh-u.ac.jp)
Get access Rights & Permissions [Opens in a new window]

Abstract

Object

We investigated an association between the polymorphism of brain-derived neurotrophic factor (BDNF) gene Val66Met and the response to mirtazapine in Japanese patients with major depressive disorder (MDD). We also examined mirtazapine's effects on the serum BDNF and plasma levels of catecholamine metabolites in these patients.

Methods

Eighty-four patients who met the DSM-IV-TR criteria for MDD were treated with only mirtazapine for 4 weeks. The BDNF Val66Met polymorphism was detected by direct sequencing in the region, and serum BDNF levels and plasma levels of catecholamine metabolites were measured by ELISA and HPLC-ECD, respectively.

Results

Mirtazapine treatment for 4 weeks significantly increased serum BDNF levels in the responders, whereas nonresponders showed significant decreases. No association was found between either of the two genotypes (Val/Val vs. Met-carriers) and the response to mirtazapine at T4 or the serum BDNF levels at T0. Mirtazapine did not alter the plasma levels of homovanillic acid (HVA) or 3-methoxy-4-hydroxyphenylglycol (MHPG).

Discussion

The dynamics of serum BDNF levels, but not plasma levels of HVA and MHPG, reflect the response to mirtazapine treatment; the BDNF Val66Met polymorphism in patients with depression is, however, associated with neither a particular response to mirtazapine treatment nor baseline serum BDNF levels.

Conclusion

Serum BDNF levels, but not plasma levels of HVA or MHPG, and BDNF Val66Met polymorphism are related to the mirtazapine response in MDD.

Keywords

brain-derived neurotrophic factormirtazapine3-methoxy-4-hydroxyphenylglycolhomovanillic acidmajor depressive disorder
Type
Original Research
Information
CNS Spectrums , Volume 17 , Issue 3 , September 2012 , pp. 155 - 163
Copyright
Copyright © Cambridge University Press 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

We thank Ms. Kazuko Shimizu for her great help in sampling. This study was supported by a Health and Labour Science Research grants from the Japanese government.

References

1.De Boer, T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 2005; 10(suppl 4): 19–23.CrossRefGoogle Scholar
2.De Montigny, C, Haddjeri, N, Mongeau, R, et al. . The effects of mirtazapine on the interactions between central noradrenergic and serotonergic systems. CNS Drugs. 1995; 4: 13–17.CrossRefGoogle Scholar
3.Duman, RS, Heninger, GR, Nestler, EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997; 54(7): 597–605.CrossRefGoogle ScholarPubMed
4.Rogoz, Z, Skuza, G, Legutko, B. Repeated treatment with mirtazapine induced brain-derived neurotrophic factor gene expression in rats. J Physiol Pharmacol. 2005; 56(4): 661–671.Google ScholarPubMed
5.Karege, F, Perret, G, Bondolfi, G, et al. . Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 2002; 109(2): 143–148.CrossRefGoogle ScholarPubMed
6.Shimizu, E, Hashimoto, K, Okamura, N, et al. . Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 2003; 54(1): 70–75.CrossRefGoogle ScholarPubMed
7.Aydemir, O, Deveci, A, Taneli, F. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29(2): 261–265.CrossRefGoogle ScholarPubMed
8.Gonul, AS, Akdeniz, F, Taneli, F, et al. . Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci. 2005; 255(6): 381–386.CrossRefGoogle ScholarPubMed
9.Sen, S, Duman, R, Sanacora, G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry. 2008; 64(6): 527–532.CrossRefGoogle ScholarPubMed
10.Brunori, AR, Lopes, M, Fregni, F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol. 2008; 11(8): 1169–1180.CrossRefGoogle Scholar
11.Bocchio-Chiavetto, L, Bagnardi, V, Zanardini, R, et al. . Serum and plasma BDNF levels in major depression: a replication study and meta-analysis. World J Biol Psychiatry. 2010; 11(6): 763–773.CrossRefGoogle Scholar
12.Mowla, SJ, Pareek, S, Farhadi, HF, et al. . Differential sorting of nerve growth factor and brain-derived neurotrophic factor in hippocampal neurons. J Neurosci. 1999; 19(6): 2069–2080.CrossRefGoogle ScholarPubMed
13.Kang, RH, Chang, HS, Wong, ML, et al. . Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. J Psychopharmacol. 2010; 24(12): 1755–1763.CrossRefGoogle ScholarPubMed
14.American Psychiatric Association. A text revision of Diagnostic and Statistical Manual of Mental Disorder, 4th ed. Washington, DC: American Psychiatric Association; 2000.Google Scholar
15.First, MB, Spitzer, RL, Gibbon, M, Williams, JBW. The Structured Clinical Interview for DSM-III-R personality disorders (SCID-II, Version 2.0): part I: description. J Personal Disord. 1995; 9: 83–91.CrossRefGoogle Scholar
16.Umene-Nakano, W, Yoshimura, R, Ueda, N, et al. . Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism. J Psychopharmacol. 2010; 24(12): 1764–1771.CrossRefGoogle ScholarPubMed
17.Yeung, PK, Buckley, SJ, Pedder, SC, et al. . Determination of 3,4-dihydroxyphenylacetic acid and 5-dihydroxyphenyleacetic acid in human plasma by a sample and rapid high-performance liquid chromatography assay. J Pharm Sci. 1996; 85(4): 451–453.CrossRefGoogle Scholar
18.Minegishi, A, Ishizaki, T. Determination of free 3-methoxy-4-hydroxyphenylglycol with several other monoamine metabolites in plasma by high-performance liquid chromatography with amperometric detection. J Chromatogr. 1984; 311(1): 51–57.CrossRefGoogle ScholarPubMed
19.Wolkowitz, OM, Wolf, J, Shellty, W, et al. . Serum BDNF levels before treatment predict SSRI response in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35(7): 1623–1630.CrossRefGoogle ScholarPubMed
20.Yoshimura, R, Hori, H, Ikenouchi-Sugita, A, et al. . Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33(4): 722–726.CrossRefGoogle ScholarPubMed
21.Yoshimura, R, Mitoma, M, Sugita, A, et al. . Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31(5): 1034–1037.CrossRefGoogle ScholarPubMed
22.Shimizu, E, Hashimoto, K, Okamura, N, et al. . Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 2003; 54(1): 70–75.CrossRefGoogle ScholarPubMed
23.Satomura, E, Baba, H, Nakano, Y, et al. . Correlations between brain-derived neurotrophic factor and clinical symptoms in medicated patients with major depression. J Affect Disord. 2011; 135(1–3): 332–335.CrossRefGoogle ScholarPubMed
24.Jevtovic, S, Kariovic, D, Mihaljevic-Peles, A, et al. . Serum brain-derived neurotrophic factor (BDNF): the severity and symptomatic dimensions of depression. Psychiatr Danub. 2011; 23(4): 363–369.Google ScholarPubMed
25.Birkenhager, TK, Geldermans, S, Van den Broek, WW, et al. . Serum brain-derived neurotrophic factor level in relation to illness severity and episode duration in patients with major depression. J Psychiatr Res. 2012; 46(3): 284–289.CrossRefGoogle ScholarPubMed
26.Zhang, Y, Gu, F, Chen, J, et al. . Chronic antidepressant administration alleviates frontal and hippocampal BDNF deficits in CUMS rat. Brain Res. 2010; 1366: 141–148.CrossRefGoogle ScholarPubMed
27.Devoto, P, Flore, G, Pira, L, et al. . Mirtazapine-induced correlate of dopamine and noradrenaline from noradrenergic neurons in the prefrontal and occipital cortex. Eur J Pharmacol. 2004; 487(1–3): 105–111.CrossRefGoogle Scholar
28.Delgado, PL, Moreno, FA, Onate, L, et al. . Sequential catecholamine and serotonin depletion in mirtazapine-treated depressed patients. Int J Neuropsychopharmacol. 2002; 5(1): 63–66.CrossRefGoogle ScholarPubMed
29.Yoshimura, R, Kishi, T, Suzuki, A, et al. . The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35(4): 1022–1025.CrossRefGoogle ScholarPubMed
30.Zou, YF, Ye, DQ, Feng, XL, et al. . Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur Neuropsychopharmacol. 2010; 20(8): 535–544.CrossRefGoogle ScholarPubMed
31.Zou, YF, Wang, Y, Liu, P, et al. . Association of brain-derived neurotrophic factor gene Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients. Neuropsychobiol. 2010; 61(2): 71–78.CrossRefGoogle ScholarPubMed
32.Chi, MH, Chang, HH, Lee, SY, et al. . Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder. J Affect Disord. 2010; 126(3): 430–435.CrossRefGoogle ScholarPubMed
33.Ozan, E, Okur, H, Eker, OD, et al. . The effect of depression, BDNF val66met polymorphism and gender on serum BDNF levels. Brain Res Bull. 2010; 81(1): 61–65.CrossRefGoogle ScholarPubMed
34.Terracciano, A, Martin, B, Ansari, D, et al. . Plasma BDNF concentration, Val66Met genetic variant and depression-related personality traits. Genes Brain Behav. 2010; 9(5): 512–518.CrossRefGoogle ScholarPubMed
35.Kendler, KS, Myers, J, Zisook, S. Does bereavement-related major depression differ from major depression associated with other stressful life events? Am J Psychiatry. 2008; 165(11): 1449–1455.CrossRefGoogle ScholarPubMed